SHR-1701
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1].
Product Specifications
CAS Number
2891860-17-4
Product Name Alternative
Retlirafusp alfa
UNSPSC
12352203
Target
PD-1/PD-L1; TGF-β Receptor
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/shr-1701.html
Purity
99.77
Solubility
10 mM in DMSO
Smiles
S[R1701]
Molecular Formula
HS
Molecular Weight
(174.61 kDa)
References & Citations
[1]Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond) . 2022 Jan;42 (1) :17-36.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
